PegBio
Suzhou
About PegBio
Founded in 2008, Suzhou city-based PegBio is a bio-pharmaceutical company specializing in the development of innovative drugs to combat diabetes and obesity. Its key product PB-119, an agonist of glucagon-like peptide 1 (GLP-1), allows diabetes patients to take medicine once a week, instead of requiring daily injections.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $145.1M
- Funding stage: IPO
- Last round: Private Equity (Dec 2020)
- Ticker: hkg:2565
- Website: pegbio.com
- Phone: +86 512-62956128
Industries & Categories
Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/pegbio-87310 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.